In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Match This
Due to considerable market growth, biosimilar clinical trials are rising in popularity. One key example relates to rituximab, and the development of its biosimilars is currently leading the way in clinical research.
-
Remote Monitoring of Patients in Clinical Trials
Recent initiatives to redesign theclinical trial processhave in part focused on the creation of trials that are more patient focused.
-
Why Sites Matter
Jennifer Byrne CEO of PMG Research contributes to this article oninvestigative sites and the drug development process.
-
Adaptive Designs for Clinical Trials
Read more aboutadaptive design for clinical trialsand how it can improve speed to market.
-
Adaptive designs patient value
Vicki Anastasi contributes to this article that looks at adaptive designs patient value and commercial benefits.
-
The Patient Data Gold Rush
Tom O'Leary's presentation to the Financial Times Digital Health Summit Europe is covered in this article regarding the use of technology tomine the clinical data patient.
-
Bring Your Own Device for Trial Outcome Assessment
A research survey to identify and assess the perceived barriers and challenges with the use ofBYOD for eCOA in clinical trials.
-
Countermeasures to Oncology Trial Failure: 5 Smarter Approaches to Trial Design and Analysis
5 Smarter Approaches to Trial Design and Analysis
Alan Phillips, Vice President, Biostatistics and Jia Ma, Senior Program Manager, Biostatistics, of ICON Clinical Research contribute to this article onCountermeasures to Oncology TrialFailures.
-
CRO Industry Update
Just as drug products have become increasingly complex, regulatory and payer demands have added a myriad of complexities and costs todrug development.
-
Postmarket Surveillance and M&A
Vicki Anastasi discusses how a merger or acquisition can impact your medical device’s post-market surveillance strategy.
